within Pharmacolibrary.Drugs.ATC.D;

model D06BB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.01,
    Cl             = 0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,
    adminCount     = 1,
    Vd             = 0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Idoxuridine is a thymidine analogue antiviral drug that interferes with viral DNA synthesis. It was primarily used topically for the treatment of herpes simplex virus infections of the eye, such as herpes simplex keratitis. Due to toxicity and more effective alternatives, its use has declined and it is rarely used today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetics for topical ocular administration in humans; no systemic pharmacokinetic data available due to poor absorption and localized use.</p><h4>References</h4><ol><li><p>Marren, K (2011). Dimethyl sulfoxide: an effective penetration enhancer for topical administration of NSAIDs. <i>The Physician and sportsmedicine</i> 39(3) 75–82. DOI:<a href=&quot;https://doi.org/10.3810/psm.2011.09.1923&quot;>10.3810/psm.2011.09.1923</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22030943/&quot;>https://pubmed.ncbi.nlm.nih.gov/22030943</a></p></li><li><p>Seth, AK, et al., &amp; Umrigar, D (2004). Topical liposomal gel of idoxuridine for the treatment of herpes simplex: pharmaceutical and clinical implications. <i>Pharmaceutical development and technology</i> 9(3) 277–289. DOI:<a href=&quot;https://doi.org/10.1081/pdt-200031432&quot;>10.1081/pdt-200031432</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15458233/&quot;>https://pubmed.ncbi.nlm.nih.gov/15458233</a></p></li><li><p>Wagstaff, AJ, et al., &amp; Goa, KL (1994). Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. <i>Drugs</i> 47(1) 153–205. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199447010-00009&quot;>10.2165/00003495-199447010-00009</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7510619/&quot;>https://pubmed.ncbi.nlm.nih.gov/7510619</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D06BB01;
